"use strict";(self.webpackChunkgenomics_docusaurus_new=self.webpackChunkgenomics_docusaurus_new||[]).push([[231],{8453:(e,n,i)=>{i.d(n,{R:()=>c,x:()=>r});var t=i(6540);const o={},s=t.createContext(o);function c(e){const n=t.useContext(s);return t.useMemo((function(){return"function"==typeof e?e(n):{...n,...e}}),[n,e])}function r(e){let n;return n=e.disableParentContext?"function"==typeof e.components?e.components(o):e.components||o:c(e.components),t.createElement(s.Provider,{value:n},e.children)}},8998:(e,n,i)=>{i.r(n),i.d(n,{assets:()=>l,contentTitle:()=>a,default:()=>p,frontMatter:()=>r,metadata:()=>t,toc:()=>d});const t=JSON.parse('{"id":"oncology-europe/incidence-cost-scenarios","title":"Incidence & Cost Scenarios","description":"High-level Genomic Sequencing Expenditure","source":"@site/docs/oncology-europe/incidence-cost-scenarios.md","sourceDirName":"oncology-europe","slug":"/oncology-europe/incidence-cost-scenarios","permalink":"/datasolutions/oncology-europe/incidence-cost-scenarios","draft":false,"unlisted":false,"tags":[],"version":"current","sidebarPosition":2,"frontMatter":{"title":"Incidence & Cost Scenarios","sidebar_position":2,"hide_title":true},"sidebar":"docsSidebar","previous":{"title":"Cancer Incidence & Projection","permalink":"/datasolutions/oncology-europe/"},"next":{"title":"German Hospital Landscape","permalink":"/datasolutions/oncology-europe/germany-hospitals"}}');var o=i(4848),s=i(8453),c=i(6025);const r={title:"Incidence & Cost Scenarios",sidebar_position:2,hide_title:!0},a=void 0,l={},d=[{value:"High-level Genomic Sequencing Expenditure",id:"high-level-genomic-sequencing-expenditure",level:2}];function u(e){const n={h2:"h2",hr:"hr",p:"p",...(0,s.R)(),...e.components};return(0,o.jsxs)(o.Fragment,{children:[(0,o.jsx)(n.h2,{id:"high-level-genomic-sequencing-expenditure",children:"High-level Genomic Sequencing Expenditure"}),"\n",(0,o.jsx)(n.hr,{}),"\n",(0,o.jsxs)("div",{style:{textAlign:"justify"},children:[(0,o.jsxs)(n.p,{children:["This section presents a ",(0,o.jsx)("strong",{children:"top-down bounding analysis"})," of potential genomic sequencing expenditure in oncology, anchored to current (2022) and projected (2050) cancer incidence."]}),(0,o.jsx)(n.p,{children:"Europe and North America are aggregated as regions where genomic testing has already achieved substantial clinical adoption, allowing projected incidence growth to be translated into an initial estimate of sequencing demand."})]}),"\n",(0,o.jsx)("br",{}),"\n",(0,o.jsxs)("div",{style:{textAlign:"justify"},children:[(0,o.jsxs)(n.p,{children:["The model assumes ",(0,o.jsx)("strong",{children:"one sequencing test per newly diagnosed cancer case"})," and explores a range of ",(0,o.jsx)("strong",{children:"uptake scenarios"}),", defined as the proportion of new cases undergoing genomic testing. Per-sample sequencing costs are varied between ",(0,o.jsx)("strong",{children:"\u20ac200 and \u20ac1000"}),", reflecting typical price ranges for ",(0,o.jsx)("strong",{children:"targeted oncology panels"}),", which remain the dominant clinical approach for identifying actionable mutations."]}),(0,o.jsxs)(n.p,{children:["These estimates intentionally represent ",(0,o.jsx)("strong",{children:"run-level sequencing cost proxies"}),", rather than fully loaded diagnostics or care-pathway costs. The objective is not precise forecasting, but to illustrate how ",(0,o.jsx)("strong",{children:"incidence growth, uptake, and unit cost jointly shape the addressable sequencing market"}),"."]})]}),"\n",(0,o.jsx)("br",{}),"\n",(0,o.jsx)("br",{}),"\n",(0,o.jsx)("img",{src:(0,c.Ay)("/files/europa_america_oncology_initial.png"),alt:"Projected sequencing costs heatmap"})]})}function p(e={}){const{wrapper:n}={...(0,s.R)(),...e.components};return n?(0,o.jsx)(n,{...e,children:(0,o.jsx)(u,{...e})}):u(e)}}}]);